MIRUM PHARMAC. DL-0001
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more
Market Cap & Net Worth: MIRUM PHARMAC. DL-0001 (08D)
MIRUM PHARMAC. DL-0001 (F:08D) has a market capitalization of $4.95 Billion (€4.82 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #3466 globally and #317 in its home market, demonstrating a 9.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MIRUM PHARMAC. DL-0001's stock price €80.50 by its total outstanding shares 59879958 (59.88 Million).
MIRUM PHARMAC. DL-0001 Market Cap History: 2021 to 2026
MIRUM PHARMAC. DL-0001's market capitalization history from 2021 to 2026. Data shows growth from $837.77 Million to $4.95 Billion (38.60% CAGR).
MIRUM PHARMAC. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MIRUM PHARMAC. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 08D by Market Capitalization
Companies near MIRUM PHARMAC. DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to MIRUM PHARMAC. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MIRUM PHARMAC. DL-0001 Historical Marketcap From 2021 to 2026
Between 2021 and today, MIRUM PHARMAC. DL-0001's market cap moved from $837.77 Million to $ 4.95 Billion, with a yearly change of 38.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.95 Billion | +21.05% |
| 2025 | €4.09 Billion | +69.64% |
| 2024 | €2.41 Billion | +42.03% |
| 2023 | €1.70 Billion | +55.06% |
| 2022 | €1.09 Billion | +30.59% |
| 2021 | €837.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of MIRUM PHARMAC. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.95 Billion USD |
| MoneyControl | $4.95 Billion USD |
| MarketWatch | $4.95 Billion USD |
| marketcap.company | $4.95 Billion USD |
| Reuters | $4.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.